AngioDynamics (ANGO) Drops -24.8% Over 30 Days: Earnings Reaction and Outlook
Key Takeaways
- AngioDynamics (ANGO) shares declined roughly 24.8% over the 30 days through early October 2026, closing near $11.52 versus about $15.32 a month earlier.
- The move was concentrated around the fiscal 2027 first-quarter earnings release: the stock fell about 21% in a single session even as results beat expectations.
- The company's Med Tech segment grew 13.2% year over year, marking an eighth consecutive quarter of double-digit growth, but investors focused on a still-loss-making bottom line.
- Management reiterated fiscal 2027 guidance and announced a planned CEO transition, adding to near-term uncertainty.
- Over the trailing three months, shares climbed from roughly $13 to a peak near $16 in late August before reversing sharply.
Company Background and Market Position
AngioDynamics, Inc. is a medical technology company based in Latham, New York, that works to restore healthy blood flow in the vascular system, broaden cancer treatment options, and enhance patient quality of life. It reports results through two segments: Med Tech and Med Device.
The faster-growing Med Tech segment features the Auryon peripheral atherectomy platform, the AlphaVac and AngioVac mechanical thrombectomy systems, and the NanoKnife irreversible electroporation platform used mainly in prostate and liver cancer procedures. The Med Device segment includes established catheter, port, and vascular access products that provide steady cash flow to support investment in the growth platforms. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors track ANGO for its ongoing shift toward higher-margin Med Tech offerings, which now represent about half of total revenue.
Stock Performance: The Last 30 Days Compared With the Quarter
Over the most recent 30 days, ANGO shares dropped approximately 24.8%, moving from a closing price near $15.32 in early September 2026 to roughly $11.52 in early October. The decline centered on the days around the fiscal 2027 first-quarter earnings release, when the stock fell about 21% in one trading session.
The quarterly view shows more movement. Shares started the period near $13 in early July, rose to an intra-quarter high close to $16 by late August amid Med Tech momentum and favorable NanoKnife reimbursement updates, then eased through September ahead of the sharp October decline. On a trailing three-month basis, ANGO is down roughly 11%, essentially returning to its starting level after the summer advance.
Earnings Report and the Sharp Market Reaction
The main driver was the fiscal 2027 first-quarter earnings report issued in early October 2026. Revenue increased 6.9% year over year to $80.9 million, and the adjusted loss per share of $0.04 beat the consensus estimate of a $0.11 loss by about 60%. Med Tech revenue rose 13.2% to $39.9 million, driven by Auryon (up 14.7%, its 21st straight quarter of double-digit growth), NanoKnife (up 29%), and AlphaVac (up 37.4%). Gross margin widened 410 basis points to 59.4%, aided partly by tariff refunds.
Even with the beat, the stock sold off sharply. The company posted a GAAP net loss of $7.1 million, used $15.3 million of cash from operations, and saw its cash balance fall to about $33.9 million. Management kept full-year guidance intact, which still points to adjusted losses, and said Eric Honroth would take over as CEO from Jim Clemmer effective November 2, 2026. The market seemed to emphasize ongoing execution, reimbursement, and competitive risks over the improving Med Tech mix, leading to a quick re-rating of the shares. I reviewed the pattern context with Tickeron’s AI Pattern Search Engine for additional perspective.
Quarterly Narrative and Strategic Developments
The broader quarterly trend reflected the company’s strategic transformation story. In mid-July 2026, ANGO reported record fiscal fourth-quarter and full-year results, with fiscal 2026 revenue of $320.2 million (up 9.4%) and Med Tech sales of $150.0 million (up 18.4%). The stock advanced on those results and on NanoKnife catalysts, including activation of Category I CPT codes for prostate and liver IRE procedures plus a Palmetto GBA local coverage determination supporting Medicare reimbursement effective July 2025.
Positive clinical updates, such as two-year PRESERVE trial data presented at the American Urological Association and FDA approvals for the RELIEF benign prostatic hyperplasia study and additional thrombectomy trials, supported the growth narrative through the summer. However, the rally lost steam as investors balanced persistent losses and cash usage against revenue momentum, setting up the October post-earnings pullback.
Key Factors to Watch Going Forward
Several items merit attention in coming quarters. Primary among them is execution on fiscal 2027 guidance of $336 million to $341 million in revenue, Med Tech growth of 12% to 15%, gross margin of 54% to 55%, adjusted EBITDA of $13 million to $16 million, and adjusted EPS between a loss of $0.29 and $0.24. The leadership change to a new CEO in November 2026 will also draw scrutiny for any shifts in strategy.
Additional expansion of NanoKnife Medicare coverage, continued enrollment in the APEX-Return, PAVE, AMBITION BTK, and RELIEF clinical studies, and progress toward sustained profitability and positive operating cash flow should remain central to the stock’s path. Macro factors such as tariffs and reimbursement trends continue to warrant monitoring as well.
AI Tools in My Research Process
One resource I turn to regularly is Tickeron’s AI Trading Bots. These automated strategies cover a range of approaches, timeframes, and risk levels, allowing me to review performance metrics and see which might align with my own analysis alongside manual research. It helps keep my process efficient without replacing core due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ANGO in downward trend: price dove below 50-day moving average on October 06, 2026
ANGO moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend. In 35 of 45 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 78%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANGO as a result. In 65 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 71%.
The 10-day moving average for ANGO crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
The Aroon Indicator for ANGO entered a downward trend on October 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +0.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANGO advanced for three days, in 201 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
ANGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 42 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.826) is normal, around the industry mean (5.011). P/E Ratio (44.843) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (0.110) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.005) is also within normal values, averaging (56.074).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. ANGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of medical devices used by radiologists, vascular surgeons and other physicians
Industry PharmaceuticalsOther
Advertisement